Audio updated on April 1, 2026, for Apple device compatibility. This article has been edited for brevity and readability.
If your angiogram was “fine,” why can a heart attack still happen? In this episode, we explain MINOCA and the AIP clue that can help flag hidden risk—and yes, there’s an AIP calculator included at the end.
🎧 ▶️ Press the play button below to listen in English.
🇨🇳 中文（简体）
🇪🇸 Spanish (Latinoamérica)
John’s Story: The Angiogram That Didn’t Predict the Heart Attack
John, in his early 50s, was overweight, had high blood pressure, and a strong family history of heart disease.
When chest pain started, his doctor ordered a stress test. John failed it. He was then referred for a coronary angiogram—the gold-standard test for finding blocked arteries.
The report came back: minimally obstructive coronary artery disease. No major blockage. John went home relieved.
Two months later, he was back in the ER with a heart attack.
This is the uncomfortable truth: An angiogram can rule out a big obstruction, but it cannot rule out the mechanisms that cause heart attacks in people with non-obstructive disease—such as plaque rupture, coronary spasm, or microvascular dysfunction.
The question becomes: If John’s angiogram looked reassuring, was there anything that could have warned us he was still at high risk?
What is MINOCA?
MINOCA stands for Myocardial Infarction with Non-Obstructive Coronary Arteries.
It is a true heart attack—with evidence of heart muscle injury—but when the patient undergoes coronary angiography, there is no major obstructive blockage (typically defined as ≤50% stenosis).
Important: MINOCA is not a final diagnosis. It is a working diagnosis that should trigger a search for the underlying mechanism.
How Common is it?
MINOCA represents approximately 5–10% of all acute coronary syndromes. It is not rare.
How Risky is it?
MINOCA is often misunderstood as a “safer” heart attack. While it may be less deadly than a heart attack with obstructive disease, it is not benign.
- 12-month all-cause mortality: ~3.5%
- Reinfarction rate: ~2.6%
A “non-obstructive” angiogram should not end the conversation—it should start the next layer of risk stratification and prevention.
The Missing Layer After Angiography: “Non-Obstructive CAD” vs “Normal Coronaries”
After John’s angiogram, the phrase “non-obstructive disease” sounded almost like “normal.” But these two labels mean very different risk.
What Do These Labels Mean?
- Normal coronaries: No visible atherosclerotic narrowing.
- Non-obstructive CAD: Visible atherosclerosis, but stenosis is not severe enough to be called obstructive (≤50%).
In other words, non-obstructive CAD still means CAD.
Why Angiography Can Miss Danger
Angiography is a picture of the lumen (the channel blood flows through). It can miss:
- Plaque vulnerability (lipid-rich, inflamed plaque)
- Positive remodeling (the vessel expands outward to hide plaque)
- Non-lumen mechanisms like spasm, microvascular dysfunction, or plaque erosion
That “hidden plaque” matters because the lumen can look preserved even when plaque burden is substantial.
The Prognosis Gap
MINOCA patients with non-obstructive CAD tend to do worse than those with completely normal coronaries.
In the AIP-MINOCA study, more than half of MINOCA patients had non-obstructive CAD. During follow-up, this group had a higher risk of major adverse cardiovascular events (MACE) than those with normal arteries.
Could John’s Heart Attack Have Been Prevented?
Guidelines describe a two-tier approach:
- First-level tests (angiography)
- Second-level tests (intracoronary imaging, vasomotor testing, cardiac MRI) to uncover the real mechanism
But in real life, many patients never get these tests due to availability, cost, or insurance barriers.
So the question becomes: What can we do that’s cheap, widely available, and still improves risk stratification after a “non-obstructive” angiogram?
That’s where the Atherogenic Index of Plasma (AIP) becomes clinically useful.
What is the Atherogenic Index of Plasma or AIP?
AIP is the base-10 logarithm of the ratio of triglycerides to HDL cholesterol:
AIP = log10(TG / HDL-C)
Important: To calculate AIP correctly, TG and HDL-C should be in mmol/L. If your lab reports in mg/dL, use a calculator that handles the conversion.
Why is This Ratio Biologically Meaningful?
- Higher triglycerides often reflect a remnant-rich, atherogenic environment.
- Lower HDL-C often travels with insulin resistance and metabolic dysfunction.
AIP doesn’t just tell you “your TG is high” or “your HDL is low.” It suggests the overall direction of your lipid terrain.
The AIP-MINOCA Study: What They Found
This study, published in the European Journal of Internal Medicine, analyzed 421 MINOCA patients separated into two angiogram categories:
- Normal coronary vessels: 188 patients (44.7%)
- Non-obstructive CAD: 233 patients (55.3%)
They calculated AIP and divided patients into four quartiles (Q1–Q4).
Finding #1: Higher AIP Was Linked to Non-Obstructive CAD
Patients in the highest AIP quartile (Q4) showed an increased likelihood of having non-obstructive CAD. Even after adjusting for other factors, AIP remained a significant predictor.
Interpretation: AIP acted like a “metabolic fingerprint” that tracked with underlying atherosclerosis—even when that atherosclerosis was not obstructive.
Finding #2: Higher AIP Predicted Worse Outcomes (More MACE)
MACE (Major Adverse Cardiovascular Events) included cardiac death, nonfatal heart attack, heart failure, stroke, and rehospitalization for angina.
Across follow-up, MACE occurred most often in the highest AIP quartile (Q4):
- Q1: 18.3%
- Q2: 18.4%
- Q3: 20.5%
- Q4: 33.6% (highest)
Even after multivariate adjustment, AIP in the highest quartile remained independently linked to MACE.
Finding #3: The “Worst-Case Quadrant”
The highest-risk group was Q4 (high AIP) + non-obstructive CAD. This combination had the greatest MACE risk compared with other groups.
How Does This Connect Back to John?
John’s angiogram showed non-obstructive CAD.
In many real-world settings, that label can accidentally translate into: “Not bad enough to worry.”
This study argues for a different mindset:
If John’s AIP had been in the highest quartile, the data suggest he would have fit into a group with substantially higher downstream event risk—despite the lack of a big angiographic blockage.
If John had both non-obstructive CAD and a very high AIP, that combination maps onto the study’s highest-risk subgroup—the exact scenario where “reassurance” is most dangerous.
Angiography answers: “Is there a major blockage today?”
AIP helps answer: “Is your lipid/metabolic terrain still pushing you toward an event?”
How AIP Can Change “What We Do Next”
A “non-obstructive” angiogram can be falsely comforting—especially if the patient hears, “No major blockage.”
The practical value of AIP is that it can push the conversation from reassurance to risk reduction.
1. AIP as a “Risk Amplifier”
If someone has:
- non-obstructive CAD on angiography
- and high AIP
…it’s a strong argument against “watch and wait.” It’s a cue to treat the situation as high-stakes prevention.
2. What Changes in the Prevention Plan When AIP is High?
A) Lifestyle becomes the main therapy—not a footnote
AIP steers attention toward the behaviors that most strongly move TG/HDL in the right direction:
- Weight and waist reduction
- Regular exercise (aerobic + resistance)
- Lowering refined carbs and added sugars
- Limiting alcohol
- Sleep and stress support
This is exactly where John failed: he left the hospital “reassured” but didn’t change the exposures feeding his risk.
B) Follow-up gets tighter
- Earlier follow-up visit
- Repeat lipids (and AIP) after lifestyle/therapy changes
- Consider broader cardiometabolic markers (HbA1c, apoB, etc.)
C) Medication conversations become more aggressive
A high AIP doesn’t prescribe a specific drug by itself, but it strengthens the case for:
- Not under-treating “mild” angiographic disease
- Not delaying aggressive metabolic/lipid risk reduction
3. Bring It Back to John
If John’s AIP had been clearly elevated, it would have shifted his discharge message from:
“No major blockage—good news.”
to:
“You’re still in a high-risk lane—here’s the prevention plan, here’s what we’re targeting, and here’s when we re-check.”
That is the core clinical translation: AIP helps decide who needs more urgency after an angiogram that looks reassuring.
IP helps decide who needs more urgency after an angiogram that looks reassuring.
The AIP Calculator
Atherogenic Index (AIP) Calculator
Calculates AIP = log10(Triglycerides ÷ HDL) using mmol/L internally.
AIP Calculator & Guidepost Values
AIP = log10(TG / HDL-C) (using mmol/L)
A common framework for classifying AIP:
- Low risk: AIP < 0.10
- Intermediate risk: AIP 0.10 – 0.24
- Higher risk: AIP > 0.24
These are guideposts, not destiny. They give you a quick way to interpret the number and decide whether this is something to take seriously.
Take-Home Summary
- MINOCA is not a “free pass” diagnosis. Outcomes can be significant.
- Within MINOCA, non-obstructive CAD carries a higher risk than completely normal coronaries—meaning “mild disease” on angiography still matters.
- AIP (Atherogenic Index of Plasma) is a simple, inexpensive marker calculated from standard lipids (triglycerides and HDL).
- In the AIP-MINOCA study, higher AIP predicted both the presence of non-obstructive CAD and a higher risk of future events.
- The highest-risk group was high AIP + non-obstructive CAD.
- AIP helps answer the question: After a “non-obstructive” angiogram, who still needs aggressive prevention?
Don’t wait until you develop chest pain, fail a stress test, or end up getting an angiogram to take your risk seriously. AIP is a snapshot of your current lipid/metabolic terrain. If you land in the intermediate- or high-risk range, that’s your cue to start now—by targeting the drivers that improve triglycerides and HDL.
These steps are the foundation of cardiovascular risk reduction, and they are the same everyday moves that tend to pull AIP down over time.
Don’t Get Sick!
About Dr. Jesse Santiano, MD
Dr. Santiano is a retired internist and emergency physician with extensive clinical experience in metabolic health, cardiovascular prevention, and lifestyle medicine. He reviews all medical content on this site to ensure accuracy, clarity, and safe application for readers. This article is for educational purposes and is not a substitute for personal medical care.
💡 Support This Work
Creating well-researched articles, maintaining this website, and keeping the information free takes time and resources.
If you found this article helpful, please consider donating to support the mission of empowering people to live healthier, longer lives, without relying on medications.
🙏 Every contribution, big or small, truly makes a difference. Thank you for your support!
Follow me on Facebook, Gab, Twitter (formerly known as X), and Telegram.
Related:
- Low LDL But Heart Attack Risk: Check AIP Now
- AIP Predicts Heart Attack Risk In Younger Adults
- AIP and Cardiovascular and Atherosclerotic Risk: A Simple TG/HDL Number That Tracks Artery Health
- Atherogenic Index (AIP): Meaning, Clinical Uses and Calculator
- Small Dense LDL: What It Means And How To Improve It
- ApoB vs LDL Cholesterol: Which Predicts Heart Attacks Better
- LDL Particle Number Explained: A Better Marker Than LDL Cholesterol
- TG/HDL Ratio Explained: What It Means and How to Improve It
- HDL Function Explained: Good vs Bad HDL
- High Triglycerides: Causes, Dangers, And How To Lower
- Metabolic Health Check: Your Metabolic Digest (What It Means + How to Improve It)
- New Science Debunks the Dangers of Saturated Fats on Heart Disease
References:
- Abdu FA, Alifu J, Mohammed AQ, Liu L, Zhang W, Yin G, Lv X, Mohammed AA, Mareai RM, Xu Y, Che W. The correlation of atherogenic index of plasma with non-obstructive CAD and unfavorable prognosis among patients diagnosed with MINOCA. Eur J Intern Med. 2024 Jul;125:111-119. doi: 10.1016/j.ejim.2024.03.024. Epub 2024 Mar 26. PMID: 38538418. https://pubmed.ncbi.nlm.nih.gov/38538418/
- Niccoli, Giampaolo, et al. “Myocardial Infarction with Non-Obstructive Coronary Arteries (MINOCA).” PMC, 2020, https://pmc.ncbi.nlm.nih.gov/articles/PMC7270909/.
- Cleveland Clinic Journal of Medicine. “Myocardial Infarction with Nonobstructive Coronary Arteries.” CCJM, 1 Dec. 2024, https://www.ccjm.org/content/91/12/743
- Spagnolo, M., et al. “Advances in the Detection and Management of Vulnerable …” Circulation: Cardiovascular Interventions, 2025, https://www.ahajournals.org/doi/10.1161/CIRCINTERVENTIONS.125.015529
- AHA (Circulation: Cardiovascular Quality and Outcomes). “Survival in Patients With Suspected Myocardial Infarction With Nonobstructive Coronary Arteries …” 2021, https://www.ahajournals.org/doi/10.1161/CIRCOUTCOMES.121.007880.
- Stepien, K., et al. “Clinical Characteristics and Long-Term Outcomes of MINOCA …” Frontiers in Cardiovascular Medicine, 2022, https://www.frontiersin.org/journals/cardiovascular-medicine/articles/10.3389/fcvm.2022.785246/full
- Tamis-Holland, James E., et al. “Contemporary Diagnosis and Management of Patients with Myocardial Infarction in the Absence of Obstructive Coronary Artery Disease: A Scientific Statement From the American Heart Association.” Circulation, 2019, https://www.ahajournals.org/doi/10.1161/CIR.0000000000000670
- American College of Cardiology. “MINOCA from A to Z.” ACC.org, 6 Jan. 2022, https://www.acc.org/Latest-in-Cardiology/Articles/2022/01/05/17/41/MINOCA-from-A-to-Z
- Yildiz, Murat, et al. “Myocardial Infarction with Non-Obstructive Coronary Arteries (MINOCA).” Frontiers in Cardiovascular Medicine, 2022, https://www.frontiersin.org/journals/cardiovascular-medicine/articles/10.3389/fcvm.2022.1032436/full
Disclaimer:
This article is for educational purposes and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your physician before making health decisions based on the TyG Index or other biomarkers.
© 2018 – 2025 Asclepiades Medicine, LLC. All Rights Reserved
DrJesseSantiano.com does not provide medical advice, diagnosis, or treatment
As an Amazon Associate, I earn from qualifying purchases
Discover more from Don't Get Sick!
Subscribe to get the latest posts sent to your email.